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Aldehydic peptides in which the C terminal residue is leucinal or phenylalaninal were synthesized. These 
compounds exhibited potent inhibition of renin activity and appeared to be precursors of transition state 
analogues for renin-catalysed amide bond hydrolysis. 
Renin Peptidyl aldehyde Enzyme inhibitor 
1. INTRODUCTION 
Pepstatin A, isovaleryl-L-valyl-L-valyl-(3&4&J- 
4-amino-3-hydroxy-6-methylheptanoic acid, was 
isolated in [l]. It strongly inhibits several carboxyl 
proteases including pepsin and renin [2-61. Many 
studies have been performed to explain its in- 
hibitory potency towards carboxyl proteases 
[7-lo] and it has been proposed that the stat- 
in [(3S,45’)-4-amino-3-hydroxy-6-methylheptanoic 
acid] residue of pepstatin is an analogue of the 
transition state for the enzyme reaction [7,1 l-131. 
Authors in [lo] have studied a keto analogue of 
statin. This peculiar inhibitor acts as an analogue 
of the substrate, undergoing nucleophilic addition 
from either water or hydroxylic ligands from the 
enzyme to give a tetrahedral intermediate, directly 
observed by r3C NMR, mimicking the aspartyl 
proteases’ transition state. 
was not so critical, we decided to test a series of 
tripeptide aldehydes of the type P-A-Y-Xh where P 
is a Boc or Z protecting group, A is an aromatic 
residue, Xh is either leucinal or phenylalaninal and 
Y is a variable residue. 
To test very short inhibitors of renin, we decided 
to synthesize aldehydic peptides. Indeed, the struc- 
ture of these products represents an ultimate shor- 
ting of the substrate, exhibiting an enhanced elec- 
trophilicity whereas the corresponding aldehyde 
hydrates resemble the shortest transition state 
analogue as shown in scheme 1. 
Many N-peptidylamino aldehydes are potential 
inhibitors towards some classes of proteolytic en- 
zymes [15-223. Authors in [21] have synthesized 
new renin inhibitors by replacing the carboxyl 
group of the Leu” residue at the C-terminus of 
angiotensin I with an aldehyde group. Z-leucinal 
semicarbazone (Z-Leu-Sem) was prepared from Z- 
Leu-OEt by reduction with diisobutylaluminium 
hydride, followed immediately by treatment with 
semicarbazide. The removal of the semicarbazide 
protecting group was performed by treatment with 
formalin-hydrogen chloride. The ICSO for hog 
kidney renin was found to be in the range of 
1OOpM indicating a poor affinity of these in- 
hibitors towards enzyme. 
This method of preparation of aldehydic pep- 
tides is thus far the only one known; it was not safe 
for the conservation of chemical and optical 
integrity. 
Our preceding studies [ 141 having shown that the 
presence of an aromatic residue in subsite S3 was 
mandatory for a good recognition by renin, 
whereas the presence of a histidine in subsite S* 
2. METHODS 
Recently we published a new method for the 
easy and racemization-proof preparation of N- 
acylamino aldehydes [23]. Notably, this method 
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Scheme 1. (Bottom) Tripeptide aldehyde hydrates as transition state analogues. (Top) The transition state and the main 
recognition subsites. 
does not require any purification of the crude pro- 
duct which can be obtained free from reduced 
alcohol contamination. We have found that the 
same method can be used to prepare peptides con- 
taining the aldehydic function at the C-terminus. 
The preparation of these peptides is described in 
[24]; the synthetic pathway is summarised in 
scheme 2. 
The enantiomeric purity of the aldehyde residue 
was established by the presence of a single 
aldehydic proton as observed by ‘H NMR at 
360 MHz. 
All the products can be produced rapidly in high 
yield and chemical purity. The limitation of the 
method lies in the failure of the attempted prepara- 
tion of histidine, containing products which were 
-> 'PFA, 
-> Boc-Y-JSU -> TF’A, Y-Leu -0Me -L 
-> P-A-Y-UN 
-xi- 
--s P-A- Y-JsucjnaJ 
Scheme 2. 
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degraded under strongly reducing conditions. 
Inhibition of human plasma renin activity was 
measured as in [25] under both acidic and 
physiological conditions. Porcine pepsin inhibition 
was measured according to known methods [2]. 
3. RESULTS AND DISCUSSION 
The measurements for 12 tripeptide aldehydes 
and one tetrapeptide are reported in table 1. They 
can be compared to the results for some single 
acylamino aldehydes, and other tripeptides bearing, 
other C-terminal functional groups. 
Every tripeptide aldehyde with an aromatic 
residue in position S3 behaves as an inhibitor as 
shown by items 7, 9-17 and 19. The aldehydic 
function is essential, as the corresponding alcohol 
3, acid 4, hydrazide 5 or methyl ketone 6 are com- 
pletely devoid of inhibitory activity. 
The inactivity of Boc-alaninal 1 and Boc- 
phenylalaninal 2 demonstrates that the inhibition 
is not the result of a non-specific reaction with pro- 
tein amino or hydroxyl groups. The inactivity of 
Table 1 
Boc-Val-Val-leucinal demonstrates that the in- 
hibitor must recognise the aromatic subsite S3. 
Though the inhibitory activity is much lower 
than the activities of recently described statin con- 
taining peptides or substrate analogues [14,26,27], 
some of these peptide aldehydes, 7, 9, 11, 14, 16 
and 19 have an equivalent or better activity at 
physiological pH than pepstatin which was the 
reference compound to this time. In contrast to the 
behaviour of pepstatin and renin inhibitors 
homologous to pepstatin, the inhibition decreased 
only a few percent from the optimal pH of the en- 
zyme to physiological pH. 
The best tripeptidic inhibitors were compared to 
pepstatin. So we could see that at physiological 
pH, the aldehydic tripeptide 11 presented an activi- 
ty towards renin 6.5times greater than pepstatin. 
On the other hand, all these products were more 
specific, being much less inhibitory towards pepsin 
than was pepstatin. 
Clearly, some of these aldehydic peptides are 
good renin inhibitors: they are the shortest and the 
simplest yet known. 
Item Inhibitors (X) 
no. 
-log ICSO renin -log zc.%J 
pepsin 
PH 6 pH 7.4 PH 6 pH 7.4 pH2 
Pepstatin (P) 5.88 4.88 7.82 
1 Boc-alaninal 
2 Boc-phenylalaninal 
3 Boc-Phe-Phe-leucinol 
4 Boc-Phe-Phe-Leu 
5 Boc-Phe-Phe-Leu-NHNHZ 
6 Boc-Phe-Phe-Leu-Me 
7 Boc-Phe-Phe-leucinal 
8 Boc-Val-Val-leucinal 
9 Z-Phe-Val-leucinal 
10 Z-Phe-Phe-leucinal 
11 Z-Trp-Val-leucinal 
12 Z-Tyr-Val-leucinal 
13 Z-Phe-Pro-leucinal 
14 Boc-Phe-Leu-leucinal 
15 Z-Phe-Be-leucinal 
16 Boc-Trp-Val-leucinal 
17 Boc-Phe-Ala-leucinal 
18 Boc-Pro-Phe-Phe-leucinal 
19 Boc-Phe-Leu-phenylalaninal 
<4 
<4 
<4 
<4 
<4 
<4 
<4 
<4 
<4 
<4 
<4 
<4 
5.79 4.96 
<4 <4 
5.40 5.26 
4.92 <4 
5.77 5.70 
4.70 <4 
c4.70 <4 
5.96 5.38 
5.16 4.82 
5.45 5.27 
5.06 4.88 
4.85 4.72 
5.43 5.68 
0.81 
0.33 2.4 
0.77 6.5 
1.2 
0.17 
0.37 
0.15 
0.35 
1.2 
3.2 
0.87 
2.5 
1.0 
0.68 
6.3 
4.40 
4.70 
<4 
<4 
<4 
<4 
<4 
4.85 
5.18 
<4 
5.52 
5.15 
<4 
<4 
5.24 
<4 
<4 
<4 
<4 
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The relatively high inhibition constants 
presented by these products in spite of the presence 
of only very few residues for subsite recognition (3 
residues only, instead of 5-8 in the inhibitors 
recently described), can be explained if these in- 
hibitors act as transition state analogues. Indeed 
the aldehydic function is susceptible to rapid 
transformation to the corresponding hydrate, 
either during the plasmatic transport, or in the ac- 
tive site itself. Scheme 1 shows clearly the struc- 
tural homology between the tripeptide aldehyde 
hydrate and the tetrahedral intermediate near the 
transition state, 
In conclusion we believe that this family of in- 
hibitors is the basis of a very practical tool for ex- 
ploring modifications at the subsites S’, S” and S3 
of renin, needing only rapid synthesis of short 
tripeptide aldehydes . 
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